Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline. Depemokimab helped ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

The GSK share price has had a rotten few years and now it’s heading south yet again. Investor Harvey Jones continues to hang on in the hope that it will recover. When investing, your capital is ...

The GSK (LSE: GSK) share price is a nightmare and there’s little sign of respite for long-suffering investors. Shares in the FTSE 100 pharmaceutical giant now trade 10.18% lower than five years ago.